|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ARL16 |
Gene summary for ARL16 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ARL16 | Gene ID | 339231 |
| Gene name | ADP ribosylation factor like GTPase 16 | |
| Gene Alias | ARL16 | |
| Cytomap | 17q25.3 | |
| Gene Type | protein-coding | GO ID | GO:0000166 | UniProtAcc | Q0P5N6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 339231 | ARL16 | LZE2T | Human | Esophagus | ESCC | 5.08e-03 | 3.43e-01 | 0.082 |
| 339231 | ARL16 | LZE3D | Human | Esophagus | HGIN | 5.07e-03 | 4.62e-01 | 0.0668 |
| 339231 | ARL16 | LZE4T | Human | Esophagus | ESCC | 1.23e-07 | 1.58e-01 | 0.0811 |
| 339231 | ARL16 | LZE7T | Human | Esophagus | ESCC | 4.87e-10 | 6.27e-01 | 0.0667 |
| 339231 | ARL16 | LZE8T | Human | Esophagus | ESCC | 9.11e-10 | 2.54e-01 | 0.067 |
| 339231 | ARL16 | LZE20T | Human | Esophagus | ESCC | 5.32e-06 | 2.19e-01 | 0.0662 |
| 339231 | ARL16 | LZE22D1 | Human | Esophagus | HGIN | 1.84e-03 | 2.38e-01 | 0.0595 |
| 339231 | ARL16 | LZE22T | Human | Esophagus | ESCC | 1.02e-06 | 5.94e-01 | 0.068 |
| 339231 | ARL16 | LZE24T | Human | Esophagus | ESCC | 1.27e-33 | 8.54e-01 | 0.0596 |
| 339231 | ARL16 | LZE21T | Human | Esophagus | ESCC | 6.46e-16 | 6.20e-01 | 0.0655 |
| 339231 | ARL16 | LZE6T | Human | Esophagus | ESCC | 8.70e-04 | 1.28e-01 | 0.0845 |
| 339231 | ARL16 | P1T-E | Human | Esophagus | ESCC | 8.08e-11 | 4.03e-01 | 0.0875 |
| 339231 | ARL16 | P2T-E | Human | Esophagus | ESCC | 1.74e-42 | 7.41e-01 | 0.1177 |
| 339231 | ARL16 | P4T-E | Human | Esophagus | ESCC | 1.83e-27 | 4.47e-01 | 0.1323 |
| 339231 | ARL16 | P5T-E | Human | Esophagus | ESCC | 9.16e-21 | 4.78e-01 | 0.1327 |
| 339231 | ARL16 | P8T-E | Human | Esophagus | ESCC | 5.66e-28 | 5.23e-01 | 0.0889 |
| 339231 | ARL16 | P9T-E | Human | Esophagus | ESCC | 1.52e-26 | 4.40e-01 | 0.1131 |
| 339231 | ARL16 | P10T-E | Human | Esophagus | ESCC | 9.79e-42 | 7.05e-01 | 0.116 |
| 339231 | ARL16 | P11T-E | Human | Esophagus | ESCC | 7.46e-21 | 8.77e-01 | 0.1426 |
| 339231 | ARL16 | P12T-E | Human | Esophagus | ESCC | 1.00e-37 | 7.34e-01 | 0.1122 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ARL16 | SNV | Missense_Mutation | novel | c.220G>T | p.Ala74Ser | p.A74S | Q0P5N6 | protein_coding | tolerated(0.41) | benign(0.119) | TCGA-BH-A0DS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide | SD |
| ARL16 | insertion | Frame_Shift_Ins | novel | c.217_218insAAAAAAG | p.Val73GlufsTer39 | p.V73Efs*39 | Q0P5N6 | protein_coding | TCGA-BH-A0DS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| ARL16 | SNV | Missense_Mutation | c.468N>G | p.Ile156Met | p.I156M | Q0P5N6 | protein_coding | tolerated(0.34) | benign(0.074) | TCGA-IR-A3LA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
| ARL16 | SNV | Missense_Mutation | c.270C>G | p.Ile90Met | p.I90M | Q0P5N6 | protein_coding | deleterious(0.02) | probably_damaging(0.996) | TCGA-LP-A4AW-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| ARL16 | SNV | Missense_Mutation | c.37N>A | p.Ala13Thr | p.A13T | Q0P5N6 | protein_coding | deleterious_low_confidence(0.02) | benign(0.003) | TCGA-CM-4743-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | capecitabine | SD | |
| ARL16 | SNV | Missense_Mutation | rs753996726 | c.526G>A | p.Ala176Thr | p.A176T | Q0P5N6 | protein_coding | deleterious(0) | possibly_damaging(0.837) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
| ARL16 | SNV | Missense_Mutation | novel | c.214N>C | p.Ile72Leu | p.I72L | Q0P5N6 | protein_coding | tolerated(0.45) | benign(0.014) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ARL16 | SNV | Missense_Mutation | rs779031827 | c.278N>A | p.Ser93Asn | p.S93N | Q0P5N6 | protein_coding | tolerated(0.17) | benign(0.38) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ARL16 | SNV | Missense_Mutation | novel | c.225N>T | p.Gln75His | p.Q75H | Q0P5N6 | protein_coding | tolerated(0.22) | benign(0.006) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
| ARL16 | SNV | Missense_Mutation | c.529N>G | p.Arg177Gly | p.R177G | Q0P5N6 | protein_coding | tolerated(0.14) | possibly_damaging(0.545) | TCGA-B5-A11I-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |